Advertisement

European Journal of Clinical Pharmacology

, Volume 5, Issue 2, pp 111–115 | Cite as

Kinetic studies on rifampicin

II. Multicompartmental analysis of the serum, urine and bile concentrations in subjects treated for one week
  • G. Acocella
  • A. Lamarina
  • F. B. Nicolis
  • V. Pagani
  • G. Segre
Originals

Summary

To aid interpretation of the fall in the serum concentrations of rifampicin observed in the early phase of continuous treatment, the distribution of the antibiotic was assessed simultaneously in the serum, bile, and urine of patients treated for one week. Transfer constants between these compartments were calculated on the 1st and 7th day of treatment by multicompartmental kinetic analysis. — The results obtained suggest that the decrease in serum concentrations is due to enhanced biliary excretion; no significant change was observed in the amount of antibiotic excreted in the urine. The increased capacity of the liver to excrete rifampicin in bile might result from enzyme induction by the antibiotic in hepatocytes.

Key words

Rifampicin kinetics multicompartmental analysis simultaneous serum urine and bile assessment one week treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Acocella, G., Pagani, V., Marchetti, M., Baroni, G.C., Nicolis, F.B.: Kinetic studies on rifampicin. I. Serum concentrations analysis in subjects treated with different oral doses over a period of two weeks. Chemotherapy16, 356 (1971).Google Scholar
  2. 2.
    Fürész, S., Scotti, R., Pallanza, R., Mapelli, E.: Rifampicin: a new rifamycin. III. Absorption, distribution and elimination in man. Arzneimittel-Forsch.17, 726 (1967).Google Scholar
  3. 3.
    Berman M.: Compartmental analysis in kinetics. In: Computers in Biomedical Research. Vol. 2, p. 173. Stacy R. W., Waxman B. D. Eds. New York: Academic Press 1965.Google Scholar
  4. 4.
    Cook, D.L., Lawler, C.A., Calvin, L.D., Green, D.M.: Mechanisms of bile formation. Amer. J. Physiol.17, 62 (1952).Google Scholar
  5. 5.
    Maggi, N., Fürész, S., Pallanza, R., Pelizza, G.: Rifampicin desacetylation in the human organism. Arzneimittel-Forsch.19, 651 (1969).Google Scholar
  6. 6.
    Riess, W., Schmid, K., Keberle, H., Dettli, L., Spring, G.: Pharmacokinetic studies in the field of rifamycins. Progress in Antimicrobial and Anticancer Chemotherapy, vol. 2, p. 905. University of Tokyo Press, 1970.Google Scholar
  7. 7.
    Jezequel, A.M., Orlandi, F., Tenconi, L.T.: Changes in the smooth endoplasmic reticulum induced by rifampicin in human and guinea pig hepatocytes. Gut12, 984 (1971).Google Scholar
  8. 8.
    Curci, G., Ninni, A., Fabbroncini, V.: Ricerche sul legame farmacoproteico e sul metabolismo della rifampicina. Rif. med.8, 3 (1970).Google Scholar
  9. 9.
    Michot, F., Bürgi, M., Büttner, J.: Rimactan (Rifampizin) und Anticoagulantien-Therapie. Schweiz. med. Wschr.100, 583 (1970).Google Scholar
  10. 10.
    De la Roy, Y.R., Beauchant, G., Breuil, K., Patte, F.: Diminution du taux sérique de rifampicine par le phénobarbital. Presse Méd.79, 350 (1971).Google Scholar
  11. 11.
    Rundle, F.F., Cass, M.H., Robson, B., Middleton, M.: Bile drainage after choledochostomy in man, with some observations on biliary fistula. Surgery37, 903 (1955).Google Scholar

Copyright information

© Springer-Verlag 1972

Authors and Affiliations

  • G. Acocella
    • 1
    • 2
    • 3
  • A. Lamarina
    • 1
    • 2
    • 3
  • F. B. Nicolis
    • 1
    • 2
    • 3
  • V. Pagani
    • 1
    • 2
    • 3
  • G. Segre
    • 1
    • 2
    • 3
  1. 1.Direzione Ricerca Clinica, Gruppo LepetitMilanoItaly
  2. 2.Divisione Chirurgica A. Ponti, Ospedale Ca'GrandaMilanoItaly
  3. 3.Istituto di Farmacologia dell'UniversitàSienaItaly

Personalised recommendations